astrazeneca logo

AstraZeneca Boosts Cancer Arsenal With 55% Acerta Pharma Stake

AstraZeneca said Thursday it would buy 55% of privately held biotech firm Acerta Pharma for $4 billion to bolster the UK pharmaceutical giant’s blood cancer treatment portfolio.

The latest deal caps an intense period of deal making for the UK drug maker as it races to refill its drug portfolio.

AstraZeneca unveils strategic transaction with Acerta Pharma
The latest deal envisages AstraZeneca paying an upfront payment of $2.5 billion for the stake and then a further unconditional $1.5 billion upon receipt . . .


This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email and we will get back to you as quick as humanly possible

Saved Articles

Are you a smart investor? Join tens of thousands of sophisticated investor reading our authoritative free newsletter

* indicates required

Congrats! Are you a smart person?

We have an exclusive targeted for being a sophisticated and loyal reader.

Sign up for ValueWalkPremium today and get our exclusive content for 35% off.

Use coupon code vip19 or click on the button below

Limited time offer only ENDS 11/30/2019 or after next 25 20 subscribers take advantage whichever comes first – please do not share this discount with others